IN2015DN01361A - - Google Patents
Info
- Publication number
- IN2015DN01361A IN2015DN01361A IN1361DEN2015A IN2015DN01361A IN 2015DN01361 A IN2015DN01361 A IN 2015DN01361A IN 1361DEN2015 A IN1361DEN2015 A IN 1361DEN2015A IN 2015DN01361 A IN2015DN01361 A IN 2015DN01361A
- Authority
- IN
- India
- Prior art keywords
- antibodies
- fusion proteins
- constant regions
- incorporating
- igg
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
The invention provides constant regions incorporating a cysteine mutation and linked to a µ tailpiece and antibodies or fusion proteins incorporating the same. The constant regions include at least CH2 and CH3 regions of an IgG heavy chain constant region including a cysteine mutation and µ tailpiece. Antibodies or fusion proteins incorporating the constant regions gains the ability to form multivalent complexes e.g. pentameric or hexameric structures. Antibodies or fusion proteins incorporating the constant regions also retain IgG properties including specific binding to protein G which facilitates purification and may exhibit pH dependent FcRn binding which is associated with a relatively long in vivo half life. Depending on the isotype and subtype the nature of the antigen and presence of an additional IgG hinge domain such antibodies or fusion proteins may also have properties of specific binding to protein A and effector functions such as ADCC, CDC and opsonization.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261679045P | 2012-08-02 | 2012-08-02 | |
US201361767724P | 2013-02-21 | 2013-02-21 | |
PCT/US2013/053086 WO2014022592A1 (en) | 2012-08-02 | 2013-07-31 | Antibodies or fusion proteins multimerized via cysteine mutation and a mu tailpiece |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2015DN01361A true IN2015DN01361A (en) | 2015-07-03 |
Family
ID=50025683
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN1361DEN2015 IN2015DN01361A (en) | 2012-08-02 | 2013-07-31 |
Country Status (7)
Country | Link |
---|---|
US (1) | US9540442B2 (en) |
EP (1) | EP2880057A4 (en) |
JP (1) | JP2015524821A (en) |
CN (1) | CN104684928A (en) |
CA (1) | CA2879814A1 (en) |
IN (1) | IN2015DN01361A (en) |
WO (1) | WO2014022592A1 (en) |
Families Citing this family (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8759297B2 (en) | 2006-08-18 | 2014-06-24 | Armagen Technologies, Inc. | Genetically encoded multifunctional compositions bidirectionally transported between peripheral blood and the cns |
AU2008282496B2 (en) | 2007-07-27 | 2013-04-04 | Armagen Technologies, Inc. | Methods and compositions for increasing alpha-iduronidase activity in the CNS |
PL2485761T3 (en) | 2009-10-09 | 2019-10-31 | Armagen Inc | Methods and compositions for increasing iduronate 2-sulfatase activity in the cns |
ES2721882T3 (en) | 2011-12-23 | 2019-08-06 | Pfizer | Constant regions of genetically engineered antibody for site-specific conjugation and procedures and uses thereof |
EP3553089A1 (en) | 2012-05-10 | 2019-10-16 | Bioatla, LLC | Multi-specific monoclonal antibodies |
IN2015DN01361A (en) | 2012-08-02 | 2015-07-03 | Jn Biosciences Llc | |
CA2939201A1 (en) * | 2014-03-05 | 2015-09-11 | Ucb Biopharma Sprl | Multimeric fc proteins |
TW201619188A (en) * | 2014-03-05 | 2016-06-01 | 優稀美生物醫藥公司 | Multimeric Fc proteins |
SI3560954T1 (en) | 2014-04-03 | 2021-11-30 | Igm Biosciences, Inc. | Modified j-chain |
EP3498295A1 (en) | 2014-05-28 | 2019-06-19 | Agenus Inc. | Anti-gitr antibodies and methods of use thereof |
MA41044A (en) | 2014-10-08 | 2017-08-15 | Novartis Ag | COMPOSITIONS AND METHODS OF USE FOR INCREASED IMMUNE RESPONSE AND CANCER TREATMENT |
US11566082B2 (en) | 2014-11-17 | 2023-01-31 | Cytiva Bioprocess R&D Ab | Mutated immunoglobulin-binding polypeptides |
ES2828037T3 (en) * | 2014-12-19 | 2021-05-25 | Jiangsu Hengrui Medicine Co | Interleukin-15 protein complex and its use |
US10538589B2 (en) * | 2015-01-14 | 2020-01-21 | Armagen Inc. | Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU |
ES2806500T3 (en) * | 2015-01-20 | 2021-02-17 | Igm Biosciences Inc | TNF (tumor necrosis factor) superfamily receptor-binding molecules and uses thereof |
IL297997A (en) * | 2015-03-04 | 2023-01-01 | Igm Biosciences Inc | Cd20 binding molecules and uses thereof |
EP3274051A4 (en) * | 2015-03-25 | 2018-08-22 | IGM Biosciences A/S | Multi-valent hepatitis b virus antigen binding molecules and uses thereof |
CN107709364A (en) * | 2015-04-07 | 2018-02-16 | 豪夫迈·罗氏有限公司 | Antigen binding complex and application method with agonist activity |
JP6811723B2 (en) * | 2015-04-17 | 2021-01-13 | アイジーエム バイオサイエンシズ インコーポレイテッド | Multivalent human immunodeficiency virus antigen-binding molecule and its usage |
KR20180015650A (en) | 2015-05-07 | 2018-02-13 | 아게누스 인코포레이티드 | Anti-OX40 antibodies and methods of use thereof |
CN108463245A (en) | 2015-09-30 | 2018-08-28 | Igm生物科学有限公司 | The binding molecule of J chains with modification |
DK3356401T3 (en) | 2015-09-30 | 2020-09-07 | Igm Biosciences Inc | BINDING MOLECULES WITH MODIFIED J-CHAIN |
CA3003033A1 (en) | 2015-10-30 | 2017-05-04 | Galaxy Biotech, Llc | Highly potent antibodies binding to death receptor 4 and death receptor 5 |
TWI778491B (en) | 2015-11-30 | 2022-09-21 | 美商輝瑞股份有限公司 | Site specific her2 antibody drug conjugates |
CA2949033A1 (en) * | 2015-11-30 | 2017-05-30 | Pfizer Inc. | Antibodies and antibody fragments for site-specific conjugation |
KR20180083944A (en) | 2015-12-02 | 2018-07-23 | 아게누스 인코포레이티드 | Antibodies and methods for their use |
KR20180098671A (en) * | 2016-01-11 | 2018-09-04 | 인히브릭스, 인크. | Multivalent and multispecific OX40-binding fusion proteins |
AU2017238172B2 (en) | 2016-03-21 | 2024-06-27 | Marengo Therapeutics, Inc. | Multispecific and multifunctional molecules and uses thereof |
US10730908B2 (en) | 2016-05-11 | 2020-08-04 | Ge Healthcare Bioprocess R&D Ab | Separation method |
CN109311948B (en) | 2016-05-11 | 2022-09-16 | 思拓凡生物工艺研发有限公司 | Method for cleaning and/or disinfecting a separation matrix |
US10654887B2 (en) | 2016-05-11 | 2020-05-19 | Ge Healthcare Bio-Process R&D Ab | Separation matrix |
US10703774B2 (en) | 2016-09-30 | 2020-07-07 | Ge Healthcare Bioprocess R&D Ab | Separation method |
ES2874974T3 (en) | 2016-05-11 | 2021-11-05 | Cytiva Bioprocess R & D Ab | Separation matrix |
WO2017194592A1 (en) | 2016-05-11 | 2017-11-16 | Ge Healthcare Bioprocess R&D Ab | Method of storing a separation matrix |
US10889615B2 (en) | 2016-05-11 | 2021-01-12 | Cytiva Bioprocess R&D Ab | Mutated immunoglobulin-binding polypeptides |
EP3487298A4 (en) * | 2016-07-20 | 2020-03-11 | IGM Biosciences, Inc. | Multimeric cd137/4-1bb binding molecules and uses thereof |
US20190338041A1 (en) * | 2016-07-20 | 2019-11-07 | Igm Biosciences, Inc. | Multimeric cd40 binding molecules and uses thereof |
AU2017359467A1 (en) | 2016-11-09 | 2019-05-02 | Agenus Inc. | Anti-OX40 antibodies, anti-GITR antibodies, and methods of use thereof |
US20200291089A1 (en) | 2017-02-16 | 2020-09-17 | Elstar Therapeutics, Inc. | Multifunctional molecules comprising a trimeric ligand and uses thereof |
US20210246227A1 (en) | 2017-05-31 | 2021-08-12 | Elstar Therapeutics, Inc. | Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof |
WO2019035938A1 (en) | 2017-08-16 | 2019-02-21 | Elstar Therapeutics, Inc. | Multispecific molecules that bind to bcma and uses thereof |
US11364303B2 (en) | 2017-09-29 | 2022-06-21 | Pfizer Inc. | Cysteine engineered antibody drug conjugates |
EP3694885A1 (en) | 2017-10-14 | 2020-08-19 | CytomX Therapeutics, Inc. | Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof |
US20210238280A1 (en) | 2018-03-14 | 2021-08-05 | Elstar Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
WO2019178364A2 (en) | 2018-03-14 | 2019-09-19 | Elstar Therapeutics, Inc. | Multifunctional molecules and uses thereof |
CN112955465A (en) | 2018-07-03 | 2021-06-11 | 马伦戈治疗公司 | anti-TCR antibody molecules and uses thereof |
KR102232659B1 (en) * | 2018-07-16 | 2021-03-26 | 전북대학교 산학협력단 | polypepide for delivery of antigen, Fc-fusion protein comprising thereof and use thereof |
KR20210044243A (en) | 2018-08-13 | 2021-04-22 | 인히브릭스, 인크. | OX40 binding polypeptides and uses thereof |
CN113453716A (en) * | 2018-12-27 | 2021-09-28 | 金德雷德生物科学股份有限公司 | Veterinary IgG Fc variants |
WO2020172601A1 (en) | 2019-02-21 | 2020-08-27 | Elstar Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
CN114126714A (en) | 2019-02-21 | 2022-03-01 | 马伦戈治疗公司 | anti-TCR antibody molecules and uses thereof |
WO2020172605A1 (en) | 2019-02-21 | 2020-08-27 | Elstar Therapeutics, Inc. | Antibody molecules that bind to nkp30 and uses thereof |
JP2022523197A (en) | 2019-02-21 | 2022-04-21 | マレンゴ・セラピューティクス,インコーポレーテッド | Multifunctional molecules that bind to T cell-related cancer cells and their use |
GB2599227B (en) | 2019-02-21 | 2024-05-01 | Marengo Therapeutics Inc | Multifunctional molecules that bind to T cells and uses thereof to treat autoimmune disorders |
EP4084821A4 (en) | 2020-01-03 | 2024-04-24 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to cd33 and uses thereof |
CA3180321A1 (en) | 2020-04-24 | 2021-10-28 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to t cell related cancer cells and uses thereof |
GB2616354A (en) | 2020-08-26 | 2023-09-06 | Marengo Therapeutics Inc | Methods of detecting TRBC1 or TRBC2 |
WO2022046920A2 (en) | 2020-08-26 | 2022-03-03 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
EP4204096A2 (en) | 2020-08-26 | 2023-07-05 | Marengo Therapeutics, Inc. | Antibody molecules that bind to nkp30 and uses thereof |
US20240067711A1 (en) | 2020-08-31 | 2024-02-29 | Medytox Inc. | Anti-vegf hexameric antibody and composition comprising same |
KR20220029343A (en) | 2020-08-31 | 2022-03-08 | (주)메디톡스 | Hexameric anti-VEGF antibody, and compositions comprising the same |
CA3214757A1 (en) | 2021-04-08 | 2022-10-13 | Andreas Loew | Multifuntional molecules binding to tcr and uses thereof |
CN115724985A (en) * | 2021-08-27 | 2023-03-03 | 三生国健药业(上海)股份有限公司 | CDC platform antibody |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020147326A1 (en) * | 1996-06-14 | 2002-10-10 | Smithkline Beecham Corporation | Hexameric fusion proteins and uses therefor |
GB9720054D0 (en) * | 1997-09-19 | 1997-11-19 | Celltech Therapeutics Ltd | Biological products |
US6475749B1 (en) * | 1999-08-11 | 2002-11-05 | The Regents Of The University Of California | Rh hybrid antibody |
US20090068178A1 (en) * | 2002-05-08 | 2009-03-12 | Genentech, Inc. | Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin |
WO2005047327A2 (en) * | 2003-11-12 | 2005-05-26 | Biogen Idec Ma Inc. | NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO |
CN101124245A (en) * | 2003-11-12 | 2008-02-13 | 比奥根艾迪克Ma公司 | Neonatal Fc receptor (FcRn)-binding polypeptide variants, dimeric Fc binding proteins and methods related thereto |
US20100297103A1 (en) * | 2006-09-14 | 2010-11-25 | Medical & Biological Laboratories Co., Ltd. | Antibody having enhanced adcc activity and method for production thereof |
GB0922209D0 (en) * | 2009-12-18 | 2010-02-03 | Univ Nottingham | Proteins, nucleic acid molecules and compositions |
EP2760891B1 (en) | 2011-09-26 | 2018-11-07 | JN Biosciences LLC | Hybrid constant regions |
IN2015DN01361A (en) | 2012-08-02 | 2015-07-03 | Jn Biosciences Llc |
-
2013
- 2013-07-31 IN IN1361DEN2015 patent/IN2015DN01361A/en unknown
- 2013-07-31 EP EP13825409.9A patent/EP2880057A4/en not_active Withdrawn
- 2013-07-31 CA CA2879814A patent/CA2879814A1/en active Pending
- 2013-07-31 JP JP2015525568A patent/JP2015524821A/en not_active Withdrawn
- 2013-07-31 WO PCT/US2013/053086 patent/WO2014022592A1/en active Application Filing
- 2013-07-31 US US13/956,121 patent/US9540442B2/en active Active
- 2013-07-31 CN CN201380041074.3A patent/CN104684928A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2014022592A1 (en) | 2014-02-06 |
US9540442B2 (en) | 2017-01-10 |
US20140037621A1 (en) | 2014-02-06 |
JP2015524821A (en) | 2015-08-27 |
EP2880057A4 (en) | 2016-03-23 |
CA2879814A1 (en) | 2014-02-06 |
EP2880057A1 (en) | 2015-06-10 |
CN104684928A (en) | 2015-06-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2015DN01361A (en) | ||
MX2020001873A (en) | Binding agents. | |
MX2010006767A (en) | Hepatitis c virus antibodies. | |
CY1120414T1 (en) | ANTIBODIES CONNECTED TO NO40 AND THEIR USES | |
CY1120412T1 (en) | ILL-31 SPECIALIZED PARTICULAR PARTS | |
MX2017006323A (en) | Antibodies comprising modified heavy constant regions. | |
NZ706232A (en) | Anti-cd3 antibodies and uses thereof | |
TR201815254T4 (en) | ANTIBODIES CONNECTED TO TL1A AND THEIR USES | |
EA201390923A1 (en) | MODIFIED ANTIBODY WITH AN IMPROVED ELEMENTATION SEMIUM PERIOD | |
IN2014MN00873A (en) | ||
AR084210A1 (en) | PROTEINS OF UNION TO TNF-a | |
NZ600262A (en) | Anti-her3 antibodies and uses thereof | |
DK2681244T3 (en) | CEA ANTIBODIES | |
MX342413B (en) | Antibodies to matrix metalloproteinase 9. | |
NZ578844A (en) | Human cytomegalovirus neutralising antibodies and use thereof | |
NZ628528A (en) | Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof | |
MX2018007630A (en) | Antibodies to matrix metalloproteinase 9. | |
NZ726258A (en) | Antibodies and uses thereof to detect folate receptor 1 | |
EA201591407A1 (en) | ANTIBODIES CONTAINING CHEMICAL CONSTANT DOMAINS | |
NZ591056A (en) | Human cytomegalovirus neutralizing antibodies and use thereof | |
NZ597447A (en) | Humanised antibodies to toll-like receptor 2 and uses thereof | |
EA201490745A1 (en) | POLYPEPTIDES OF ANTIBODIES THAT CAUSE ANTAGONISM CD40L | |
UA106070C2 (en) | Antibody that specifically binds to egfr and her3 | |
NZ594682A (en) | Fully human antibodies specific to cadm1 | |
PH12014501931A1 (en) | Antibodies to matrix metalloproteinase 9 |